Application of Acanthopanax trifoliatus polysaccharide ATP1-1 in preparation of medicines for treating diabetes mellitus

Abstract

The invention discloses application of Acanthopanax trifoliatus polysaccharide ATP1-1 in preparation of medicines for treating diabetes mellitus. Tests have proven that the ATP1-1 is capable of alleviating the symptom of weight loss in mice with diabetes mellitus, as well as promoting weight gain of the mice; the ATP1-1 has blood glucose reduction effects on mice with diabetes mellitus, and is capable of enhancing control over blood glucose and decreasing fluctuation of blood glucose so as to achieve the effect of treating diabetes mellitus; the ATP1-1 is capable of effectively reversing the change of insulin reduction induced by islet injury; the ATP1-1 has curative effects of various degrees on pancreas islets of mice, and is capable of inhibiting apoptosis of islet cells; and the ATP1-1is capable of effectively repairing spleen injury, and regulating immune functions of the body. The acanthopanax trifoliatus is a purely natural plant which can be developed and utilized so as to reduce side effects caused by western medicines; moreover, the highest content of the acanthopanax trifoliatus polysaccharide is found in stem of the acanthopanax trifoliatus, thereby bring the advantageof being low in price. Thus, development of the blood glucose reduction effects of the acanthopanax trifoliatus is endowed with extremely high economic values.

Description

technical field [0001] The invention relates to a new application of Bougainvillea polysaccharide ATP1-1, in particular to the application of Bougainvillea polysaccharide ATP1-1 in the preparation of medicines for treating diabetes. Background technique [0002] At present, diabetes has become the third chronic disease that seriously threatens human health after tumors and cardiovascular diseases. Diabetes is an increasingly serious problem in both developed and developing countries. It has caused serious and costly consequences, including Blindness, heart disease, kidney disease, and complications from diabetes. According to the estimates of the International Diabetes Federation, the number of diabetic patients in China will exceed 50 million in the next 20 years. Diabetes now tends to expand and rejuvenate. How to prevent and treat diabetes has become a major topic of focus in the medical field. [0003] At present, the drugs for treating diabetes that are widely used in...

AI Technical Summary

Problems solved by technology

ATP1 was subjected to repeated Sephadex G-75 Sephadex column chromatography to obtain neutral polysaccharide ATP1-1 with uniform molecular weight, but the previous studies did not disclose the effect of ATP1-1 on diabetes

The invention patent with the patent application number 2013100356079 discloses the application of bougainvillea polysaccharides in the preparation of drugs for treating diabetes. However, it is well known that the extraction method of bougainvillea polysaccharides at that time was relatively traditional, and the polysaccharides contained a large amount of nucleic acids, proteins and peptides, etc. Impurities, the product has low purity and is a mixture of various components. Therefore, under the technical background at that time, the polysaccharide ATP1-1 could not be isolated, and it was impossible to determine whether the ATP1-1 isolated from the bougainvillea polysaccharide had Conclusions on positive effects of coping with diabetes

The invention patent with the patent application number of 2016110462538 discloses a method for separating and purifying polysaccharides from bougainvillea to obtain neutral and uniform polysaccharide ATP1-1, which solves the problem of insufficient separation and purification of polysaccharides from bougainvillea and low purity. The present invention provides the basis for research

Images